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Abstract An improved, scalable synthetic route to the quinazolinone natural 
product 2,3-dihydropyrrolo[1,2-a]quinazolin-5(1H)-one is reported. The 
applicability of this method to analogue synthesis and the synthesis of 
related natural products is explored. Finally, reactivity of the scaffold to a 
variety of electrophilic reagents, generating products stereoselectively, is 
reported.  	
Key words quinazolinone, alkaloid, 2,3-dihydropyrrolo[1,2-a]quinazolin-
5(1H)-one, deoxyvasicinone Quinazolinone	 alkaloids	 are	 commonly	 found	 as	 the	 structural	basis	 of	 natural	 products	 and	 pharmaceuticals	 that	 display	biological	 activities	 in	 diverse	 areas,	 including	 cancer,	 CNS	systems,	 inflammation,	 and	 hypertension.2,3	 Many	quinazolinone	 alkaloids	 contain	 the	 quinazolinone	 ring	 fused	with	pyrrole	or	piperidine	rings.4	These	are	often	derivatives	of	deoxyvasicinone	 (1)	 or	 vasicinone	 (2),	 isolated	 from	Adhatoda	
vasica,	 and	 mackinazolinone	 (3),	 isolated	 from	 Mackinalaya	species	 (Figure	 1).5,6	 These	 alkaloids	 have	 been	 extensively	studied	and	a	wide	variety	of	 routes	 for	 their	synthesis,	and	of	their	derivatives,	have	been	developed.4		
 
Figure 1 Quinazolinone alkaloids with fused pyrrole or piperidine rings 
demonstrate a variety of biological activities 
2,3	 Dihydropyrrolo[1,2-a]quinazolin-5(1H)-one	 (4),	 an	 isomer	of	deoxyvasicinone	(1),	was	only	isolated	as	a	natural	product	in	2015,	 from	 Castanea	 crenata	 Sieb	 (Chestnut	 honey).7	 It	 has,	however,	been	obtained	by	synthetic	methods	for	much	longer.8	The	 biological	 activities	 of	 4	 and	 derivatives	 based	 on	 its	alkaloid	core	have	not	been	extensively	 investigated	compared	with	related	alkaloids	1	and	2.	A	brominated	derivative	of	4	has	some	 antibacterial	 activity	 at	 μg/mL	 levels	 against	 Bacillus	
subtilis	 and	 fungicidal	 activity	 against	 Candida	 albicans	 and	
Aspergillus	 niger.9	 Compounds	 containing	 a	 core	 2,3	dihydropyrrolo[1,2-a]quinazolin-5(1H)-one	motif	were	found	to	be	 inhibitors	 of	 proteins	 in	 the	 bromodomain	 family	 of	epigenetic	reader	proteins.10	In	 order	 to	 fully	 explore	 the	 potential	 of	 compound	 4	 as	 a	scaffold	 for	 pharmaceutical	 or	 agrichemical	 applications	 a	robust,	 readily	 adaptable	 synthetic	 route	 to	 4	 and	 related	analogues	 would	 be	 useful.	 Alkaloid	 4	 has	 been	 synthesized	through	 several	methods	 (Scheme	 1).	 However,	 some	 of	 these	routes	were	 low	 yielding	 or	would	 be	 unsuitable	 for	 analogue	synthesis	due	to	the	starting	materials	or	reagents	used.11–14	Furthermore,	work	has	not	been	extensively	undertaken	to	test	the	 reactivity	 of	 the	 scaffold	 and	 explore	 its	 chemistry	 in	comparison	to	the	related	deoxyvasicinone	1.	 	 In	this	paper	we	report	 the	 development	 of	 an	 improved	 synthetic	 route	 to	 4,	exploration	of	the	scope	of	the	route,	and	investigations	into	the	reactivity	 of	 4.	 Our	 synthetic	 route,	 based	 on	 the	 existing	synthesis	 by	 Dunn	 et	 al.,12	 enabled	 the	 reliable	 and	 rapid	preparation	of	4	at	 reasonable	 scale	and	with	good	yields.	Our	strategy	uses	inexpensive	reagents	and	was	found	to	be	readily	adaptable	 for	 the	 synthesis	 of	 analogues	 and	 some	 related	compounds.	 With	 a	 route	 that	 generated	 4	 in	 appreciable	quantities,	 we	 also	 investigated	 the	 reactivity	 of	 the	 scaffold,	highlighting	the	weakly	nucleophilic	characteristics	of	the	core.		
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Scheme 1 Summary of some existing synthetic routes to 2,3 
dihydropyrrolo[1,2-a]quinazolin-5(1H)-one 4 
Optimisation	 of	 a	 synthesis	 to	 2,3-dihydropyrrolo[1,2-
a]quinazolin-5(1H)-one,	4	The	 route	 to	 2,3-dihydropyrrolo[1,2-a]quinazolin-5(1H)-one	reported	by	Dunn	et	al.	was	chosen	for	exploration,	since	it	used	readily	 accessible,	 inexpensive	 reagents	 and	 we	 proposed	 it	would	be	able	 to	 tolerate	substitution.12	 In	agreement	with	 the	literature	 procedure,	 reaction	 of	 anthranilamide	 5	 with	 acid	chloride	 6	 gave	 the	 precursor	 secondary	 amide	 7.	 Cyclisation	using	sodium	methoxide	gave	the	two	isomers	deoxyvasicinone	
1	 and	 the	 desired	 compound	 2,3-dihydropyrrolo[1,2-a]quinazolin-5(1H)-one	 4	 in	 low	 yields	 comparable	 to	 those	reported	(Table	1).		We	proposed	that	yields	might	be	improved	by	use	of	a	stronger	base.	 Reaction	 of	 secondary	 amide	 7	 with	 two	 equivalents	 of	potassium	tert-butoxide	(tBuOK)	in	THF	led	to	rapid	cyclisation,	with	 some	 reactions	 complete	 in	 less	 than	 10	 minutes.	 A	significant	 switch	 in	 product	 distribution	 was	 observed,	 with	more	of	the	desired	isomer	4	rather	than	1	being	produced,	and	the	 overall	 yield	 was	 also	 greatly	 increased.	 Another	 strong	base,	 NaHMDS,	 also	 demonstrated	 this	 effect,	 but	 tBuOK	 was	used	subsequently	due	to	its	lower	cost	and	ease	of	use.	
Table 1 Optimisation of Reaction Conditions for the Cyclisation of 7 to 4a 
 
      
Entry Base Eq. Time Yield 4(%) Yield 1 (%) 
1 25% wt NaOMe 10 4.00 13 19 
2 tBuOK 1 4.00 35 22 
3 tBuOK 2 0.25 77 15 
4 tBuOK 3 0.25 59 29 
5 NaHMDS 2 0.25 71 24 
a Reaction conditions: (a) Et3N (2.0 eq), THF, 0 °C to rt, 12 h, 92%; (b) base 
(equivalents), THF, time. 
 The	 two	 isomers	 could	 be	 separated	 readily	 by	 flash	 column	chromatography	(FCC)	rather	than	using	a	Soxhlet	extractor	as	reported.12	 Identification	 of	 the	 isomers	was	 confirmed	 by	 the	presence	of	a	strong	nOe	signal	in	4	between	the	aromatic	ring	and	pyrrole	ring	as	well	as	the	large	difference	in	their	melting	points.	The	reaction	was	also	performed	on	a	gram	scale,	using	
7,	with	yields	up	to	69%	being	reliably	obtained	on	this	scale.	
Versatility	of	the	synthetic	route	for	analogue	synthesis		An	advantage	of	this	route	was	the	accessibility	of	substituted	2-aminobenzamides,	 enabling	 the	 robustness	 of	 the	 route	 for	analogue	 synthesis	 to	 be	 tested.	 A	 range	 of	 substituted	 2-aminobenzamides	were	obtained	through	a	variety	of	routes,15–17	 of	 which	 microwave	 assisted	 hydrolysis	 from	 2-aminobenzonitriles	 proved	 the	 most	 versatile	 and	 reliable	method	 (see	 Supporting	 Information).18	 These	 2-aminobenzamides	 were	 then	 reacted	 with	 acid	 chloride	 6	 as	before	 (Table	 2).	 Open	 chain	 intermediates	 8-18	 could	 be	accessed	 in	 moderate	 to	 excellent	 yields,	 with	 a	 variety	 of	substitution	 patterns	 being	 tolerated,	 although	 substitution	
ortho	to	the	amine	was	low	yielding	for	steric	reasons.	These	 secondary	 amides	 were	 then	 reacted	 with	 tBuOK	 and	cyclised	 successfully	 with	 good	 functional	 group	 tolerance.	However,	 the	 yields	 and	 ratio	 of	 isomers	 obtained	 were	sensitive	 to	 substitution	 pattern.	 Substitution	 meta	 to	 the	secondary	 amide	 generally	 gave	 the	 best	 yields	 and	 the	 most	favourable	 isomer	 distribution	 for	 the	 desired	 2,3-dihydropyrrolo[1,2-a]quinazolin-5(1H)-one	 products.	 For	example,	 on	 cyclisation	 of	 chlorinated	 intermediate	 17	 the	desired	 product	28	 was	 obtained	 in	 91%	 yield	 after	 FCC,	 and	none	of	the	alternative	isomer	was	detected	by	crude	NMR..	The	methodology	was	 also	 tested	with	 electron	 poor	 systems,	and	the	nucleophilicity	of	the	primary	amine	was	found	to	be	a	key	determinant	of	reactivity.	Reaction	of	2-aminonicotinamide	failed	 to	 give	 the	 desired	 product;	 instead	 compound	 30,	product	 of	 the	 reaction	 of	 both	 the	 primary	 amine	 and	 the	primary	 amide,	 was	 isolated	 (Scheme	 2).	 By	 contrast,	 3-aminonicotinamide	could	be	successfully	reacted	to	give	31,	as	the	electron-withdrawing	group	was	not	in	direct	
 
Scheme 2 Use of electron poor nicotinamides to generate analogues of 4. 
Reaction conditions: (a) 4-chlorobutanoyl chloride (1.2 eq), Et3N (2.0 eq), 
THF, 0 C to rt, 21%; (b) 4-chlorobutanoyl chloride (1.5 eq), Et3N (1.5 eq), THF, 
0 C to rt, 12 h, 58%; (c) tBuOK (2.0 eq), THF (0.1 M), rt, 2 h, 31%.  
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Table 2 Synthesis of substituted 2-aminobenzonitriles and subsequent reaction with 4-chlorobutanoyl chloride and cyclisation to give analogues of 4 
 
       
Entry R Compound  
Number 
Yield 8-18  Compound Number  Yield 19-29 Yield alternate 
isomerc 
1 3-Me 8 39 19 53 26 
2 4-Me 9 94 20 74 11 
3 5-OMe 10 52 21 20 15 
4 5-Me 11 79 22 37 8 
5 5-F 12 93 23 33 6 
6 5-Cl 13 81 24 65 24 
7 6-OMe 14 79 25 82 - 
8 6-Me 15 60 26 90 <4 
9 6-F 16 94 27 73 <5 
10 6-Cl 17 93 28 96 <1 
11 6-Br 18 78 29 88 <5 
a 4-Chlorobutanoyl chloride (1.2 eq), Et3N (2.0 eq), THF, 0 °C to rt, 4 h to 24 h; 
b tBuOK (2.0 eq), THF (0.1M), 1 h; c Yields were determined on the basis of a crude NMR and 
subsequent purification of the major product.  	
 	conjugation	 with	 the	 primary	 amine.	 This	 amide	 was	 then	successfully	cyclised	to	compound	32	in	31%	yield.		
Generation	of	expanded	ring	analogues	Analogues	 of	 the	 scaffold	 with	 an	 expanded	 aliphatic	 ring	system,	 such	 as	 mackinazolinone	 3,	 have	 been	 synthesised	previously	 using	 the	methods	 of	 Dunn,12	 Sun,13	 and	 Jones14	 as	highlighted	 in	 Figure	 1,	 amongst	 many	 others.4	 We	 assessed	whether	 our	 improved	 synthetic	 route	would	 be	 applicable	 to	these	 systems.	 Pre-cursor	 compounds	 33	 and	 34	 were	synthesised	 using	 the	 appropriate	 acid	 chloride	 in	 79%	 and	86%	 yield	 respectively.	 Cyclisation	 of	 33	 with	 tBuOK	 led	 to	mackinazolinone	 (3)	 in	 92%	 yield,	 rather	 than	 the	 isomer	analogous	to	4.	Similarly,	compound	34	gave	41	in	52%	with	no	isolation	of	38	(Table	3).	However,	substitution	of	the	aromatic	ring	affected	the	product	distribution.	Unlike	the	unsubstituted	system,	 cyclisation	 of	 chlorinated	 amide	35	 bearing	 a	 chlorine	group	gave	access	 to	both	 isomers	39	 and	42	 in	yields	of	51%	and	 48%	 respectively.	 However,	 cyclisation	 of	 36	 gave	 only	compound	43	in	20%	yield.		
Table 3 Synthesis of analogues with expanded ring systemsa 
 
        
Entry R n Starting 
material 
Product 
A 
Yield 
(%) 
Product 
B 
Yield 
(%) 
1 H 2 33 37 0 3 92 
2 H 3 34 38 0 41 52 
3 Cl 2 35 39 51 42 48 
4 Cl 3 36 40 0 43 20 
a tBuOK (2.0 eq), THF, rt 
	
Proposed	mechanism	All	 these	 observations	 taken	 in	 combination	 agree	 with	 the	report	 that	 the	 system	 can	be	 cyclised	 through	 two	 competing	mechanisms.19	We	 suggest	 that	 use	 of	 stronger	 bases,	 such	 as	
tBuOK,	 favours	 deprotonation	 of	 the	 secondary	 amide	 in	 7	followed	by	 5-exo-tet	 cyclisation	 and	 subsequent	 condensation	of	the	lactam	with	the	primary	amide	(route	A).	However,	when	the	 chain	 length	 increases	 the	 lactamization	 is	 slower.	 Instead,	the	 condensation	 of	 the	 primary	 amide	 onto	 the	 secondary	amide	 in	7	may	 occur	 first	 followed	 by	 subsequent	 cyclisation	(route	B).	As	these	routes	would	be	in	competition,	their	relative	rates	determine	product	distribution.		Changing	the	electronics	of	the	ring	will	affect	both	the	acidity	of	the	 secondary	 amide	 and	 the	 electrophilicity	 of	 the	 primary	amide,	 altering	 the	 ratio	 of	 isomers	 produced.	 No	 lactam	intermediates	 from	 proposed	 route	 A	were	 isolated.	 However,	with	 chlorinated	 substrates	 35	 and	 36,	 with	 longer	 chain	lengths,	 reactions	 were	 stopped	 prior	 to	 completion,	 and	intermediates	42a	 and	43a	 could	 be	 isolated	 in	 9%	 and	 95%	yield	respectively,	providing	some	evidence	for	the	existence	of	route	B	(Figure	2).		
 
Figure 2 Intermediates in the cyclisation of longer chain amides that could 
be isolated 
C-Nucleophilicity	 of	 the	 2,3-dihydropyrrolo[1,2-
a]quinazolin-5(1H)-one	scaffold	2,3-Dihydropyrrolo[1,2-a]quinazolin-5(1H)-one	 4	 is	 closely	related	 to	 the	 alkaloid	 deoxyvasicinone	 1	 and,	 like	deoxyvasicinone,	 shows	 reactivity	 towards	 electrophilic	reagents	at	the	C3	carbon	position.20	In	studies	of	the	scaffold	as	
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the	 basis	 for	 polymethine	 dyes,	 4	 was	 shown	 to	 react	 with	conjugated	 aldehydes	 and	 condensed	 with	 benzaldehyde.12,21	We	 conducted	 initial	 investigations	 into	 the	 extent	 of	 this	reactivity	using	a	variety	of	electrophilic	reagents	to	generate	a	series	of	substituted	derivatives	of	compound	4.		
Reaction	with	aromatic	aldehydes	The	reaction	of	4	with	aromatic	aldehydes	was	studied	first.	As	reported,	heating	alkaloid	4	with	benzaldehyde	with	acetic	acid	and	sodium	acetate	led	to	rapid	condensation	and	formation	of	the	 alkene	 44	 (Scheme	 3).12	 None	 of	 the	 intermediate	 aldol	product	 was	 isolated,	 likely	 due	 to	 the	 stability	 of	 the	 highly	conjugated	product.	Only	one	stereoisomer,	44,	was	obtained	in	94%	yield	and	given	the	thermodynamic	conditions	used,	the	E	geometry	was	proposed	to	be	favoured.	This	was	confirmed	by	nOesy	 experiments;	 a	 distinctive	 interaction	 between	 the	condensed	 aromatic	 ring	 and	 the	 aliphatic	 ring	 was	 observed,	whilst	 the	potential	 interaction	between	the	alkene	proton	and	ring	in	proposed	Z	isomer	were	not	identified	(Scheme	3B).	The	methodology	 was	 applicable	 to	 substituted	 aldehydes:	 both	electron	 withdrawing	 and	 electron	 donating	 groups	 were	tolerated	to	give	the	final	products	45	and	46	in	94%	and	66%	yield	 respectively.	 The	 solubility	 of	 these	 products	 in	 both	organic	and	aqueous	solvent	was	low.		
 
Scheme 3 A) Reaction of 4 with aromatic aldehydes. Reaction conditions: 
(a) aromatic aldehyde, NaOAc, AcOH, 110 °C, 6 h. B) Proposed characteristic 
nOes in 44 and its alternative Z isomer.  
Reaction	with	aliphatic	aldehydes	Unlike	 aromatic	 aldehydes,	 refluxing	 aliphatic	 aldehydes	 with	2,3-dihydropyrrolo[1,2-a]quinazolin-5(1H)-one	4	 in	 acetic	 acid	gave	an	inseparable	mixture	of	unidentified	products.	However,	treatment	 of	 the	 scaffold	 with	 tBuOK	 to	 form	 an	 extended	enolate	 and	 subsequent	 addition	 of	 2-ethylbutyraldehyde	 at	room	 temperature	 led	 to	 aldol	 reaction	 and	 then	 E1cb	elimination	 of	water,	 to	 give	47	 as	 the	E	 isomer	 in	 69%	 yield	(Scheme	 4).	 The	 chemistry	 tolerated	 functionalization	 of	 the	aromatic	ring	and	varied	aldehydes,	for	example	in	synthesis	of	compound	 49	 and	 50.	 In	 some	 cases	 the	 intermediate	 aldol	products	could	be	isolated	as	a	1:1	mixture	of	diastereoisomers.		
Reaction	with	formamides	Analogous	 to	 reported	 reactions	 with	 deoxyvacisinone,22	scaffold	4	was	reacted	with	phosphoryl	chloride	in		
 
Scheme 4 Reactions of 2,3-dihydropyrrolo[1,2-a]quinazolin-5(1H)-ones with 
aliphatic aldehydes. Conditions: (a) tBuOK, CH2Cl2, 10 min, then aldehyde. dimethylformamide	 at	 60	 °C	 in	 a	 Vilsmeier-Haack	 style	formylation,	 giving	 the	dimethylaminomethylene	derivative	51	in	 74%	 yield	 (Scheme	 5).	 The	 E	 isomer	 alone	 was	 observed	under	 the	 thermodynamic	control	of	 these	 reaction	conditions.	No	aldehyde	product	from	imine	hydrolysis	was	observed,	likely	due	 to	 the	 stability	 of	 the	 conjugation	 of	 the	dimethylaminomethylene	system	once	formed.	The	chemistry	could	be	extended	to	other	simple	formamides	to	give	 aminomethylene	 derivatives	 such	 as	 52	 and	 53	 in	moderate	 yield.	 Formamides	 containing	 additional	 nitrogen	groups	such	as	1-methylpiperazine	did	not	give	products	using	these	conditions.	The	dimethylaminomethylene	product	51	was	weakly	 reactive	 to	 nucleophilic	 substitution,	 allowing	 further	elaboration	 of	 the	 dihydropyrrolo[1,2-a]quinazolin-5(1H)-one	core.	Upon	refluxing	with	excess	secondary	amine	and	catalytic	DMAP,	 the	 dimethyl	 group	 in	 51	 could	 be	 displaced	 giving	compounds	54-56.		Ring-expanded	analogues	such	as	39	could	also	be	reacted	using	this	methodology	to	give	derivatives	57	and	58	in	48%	and	89%	yield	respectively	(Scheme	6).		
  
Scheme 5 	 Reaction of 4 and related analogues with formamides and 
amines. Conditions: (a) POCl3, DMF, 70 °C, 3 h, 74%; (b) formamide, POCl3, 
CH2Cl2, 50 °C, 3-48 h; (c) amine, DMAP, EtOH, 70 °C, 24-96 h  These	 reactions	 indicate	 the	 reactivity	 of	 the	 2,3	dihydropyrrolo[1,2-a]quinazolin-5(1H)-one	core	 to	a	variety	of	electrophiles	is	comparable	to	deoxyvasicinone	1.	The	latter	can	be	 brominated	 and	 oxidised,	 and	 other	 similar	 reactivity	 may	also	applicable	to	4.	In	these	reactions	nucleophilicity	was	only		
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Scheme 6 (a) POCl3, DMF, 70 °C, 6 h, 49%; (b) 1-methylpiperazine, DMAP, 
EtOH,  70 °C, 6 h, 89% observed	at	carbon	3.	When	this	position	is	blocked,	for	example	in	 isoindolo[2,1-a]quinazoline-5-ones,23	 carbon	 1	 directly	adjacent	 to	 the	 nitrogen	 becomes	 the	 most	 reactive	 to	electrophiles.		In	 conclusion,	 a	 versatile,	 scalable	 synthetic	 route	 to	 the	 2,3	dihydropyrrolo[1,2-a]quinazolin-5(1H)-one	 4	 has	 been	optimised,	 and	 shown	 to	 be	 suitable	 for	 the	 synthesis	 of	 a	variety	 of	 analogues	 and	 some	 related	 compounds.	 The	nucleophilic	 reactivity	 of	 4	 and	 analogues	 has	 been	demonstrated	with	a	variety	of	electrophiles.	Condensation	with	electron-poor	 and	 electron-rich	 aromatic	 aldehydes	 occurs	 in	acidic	medium	whilst	aliphatic	aldehydes	can	be	reacted	under	basic	conditions,	 in	both	cases	stereoselectively.	Additionally,	4	has	 been	 derivatised	 using	 Vilsmeier	 condensation	 chemistry,	and	 the	 products	 of	 this	 reaction	 such	 as	 51	 can	 be	 used	 to	access	 other	 compounds	 through	 nucleophilic	 displacement.	These	 results	 enable	 the	 synthesis	 of	 a	 wider	 variety	 of	structures	 based	 on	4	 than	 previously	 demonstrated,	 allowing	their	chemical	and	biological	activity	to	be	explored.		The	experimental	section	has	no	title;	please	leave	this	line	here.	All	reactions	were	performed	using	oven-dried	glassware	(200	°C)	under	a	 dry	 argon	 atmosphere	 unless	 otherwise	 stated	 or	 aqueous	 reagents	were	 employed.	All	 solvents	 used	 in	 reactions	were	 dried	 and	distilled	according	 to	 standard	protocols.	All	 reagents	were	used	as	 supplied	or	purified	using	standard	procedures	as	necessary.		Flash	column	chromatography	(FCC)	was	performed	using	Sigma	Aldrich	silica	gel	pore	size	60	Å,	230	–	400	mesh	under	air	pressure.	The	solvents	used	 for	 FCC	 were	 distilled	 before	 use.	 “Hexanes”	 refers	 to	 petroleum	ether	 distillate	 (boiling	 point	 –	 40-60	 °C).	 Analytical	 thin	 layer	chromatography	(TLC)	was	performed	using	silica	gel	60	F254	pre-coated	glass-backed	 plates	 and	 visualised	 by	 ultraviolet	 radiation	 (254	 nm),	potassium	permanganate	or	ninhydrin	 as	 appropriate.	 Preparative	TLC	was	performed	using	silica	gel	GF	500	micron	UNIPLATES	(Analtech).	1H	NMR	spectra	were	recorded	on	Bruker	Avance	DPX-600	(600	MHz),	Bruker	DPX-400	(400	MHz)	or	Bruker	DCH	Cryoprobe	(500	MHz).	High	resolution	 mass	 spectrometry	 (HRMS)	 was	 performed	 on	 a	 Waters	Micromass	LCT	Premier	spectrometer	using	electrospray	ionisiation	and	Micromass	MS	software,	or	on	a	ThermoFinnigan	Orbitrap	Classic	using	positive	ion	electrospray.	Infrared	spectra	were	recorded	as	thin	films	on	a	 Perkin-Elmer	 Spectrum	One	 FTIR	 spectrometer.	Melting	 points	were	collected	using	a	Stanford	Research	Systems	Optimelt	automated	melting	point	system	using	a	gradient	of	1	°C	per	min.		
Procedures	
Synthesis	of	2-(4-chlorobutanamido)-benzamides:	general	procedure	A		
A	solution	of	the	appropriate	substituted	2-aminobenzamide	(1.0	eq)	in	THF	(2.5	mL	per	mmol	substrate)	was	cooled	to	0	°C	and	triethylamine	(2.0	 eq)	 then	 the	 appropriate	 acid	 chloride	 (1.2	 eq)	 in	 THF	 (2	mL	 per	mmol	 substrate)	were	 added	 to	 the	 stirred	 solution.	 The	 reaction	was	stirred	at	room	temperature	until	completion	as	indicated	by	TLC,	when	the	mixture	was	diluted	with	EtOAc	and	quenched	with	NaHSO4	(20	mL).	The	 aqueous	 phase	 was	 extracted	 with	 EtOAc	 (3	 ×	 20	 mL),	 combined	organic	phases	dried	over	MgSO4,	excess	solvent	removed	 in	vacuo	and	the	residue	purified	by	FCC.			
Synthesis	 of	 2,3-dihydropyrrolo[1,2-a]quinazolin-5(1H)-ones:	 general	
procedure	B	To	 a	 solution	 of	 the	 appropriate	 substituted	 2-(4-chlorobutanamido)-benzamides	substrate	(1.0	eq)	 in	THF	(10	mL	per	mmol	substrate)	was	added	 tBuOK	 (2.0	 eq).	 The	 reaction	 was	 stirred	 at	 room	 temperature	until	TLC	indicated	completion,	then	solvent	was	removed	 in	vacuo,	 the	resulting	 residue	 re-dissolved	 in	CH2Cl2	 (20	mL)	 and	NaHCO3	 (15	mL),	and	the	aqueous	layer	extracted	with	CH2Cl2	(5	×	20	mL).	The	combined	organic	 phases	were	 dried	 over	MgSO4	 and	 solvent	 removed	 in	 vacuo.	The	products	were	obtained	after	purification	of	the	residue	by	FCC.		Characterisation	 data	 for	 selected	 compounds	 are	 reported	 below.	 For	other	analogues	please	see	further	data	in	supporting	information.		
Deoxyvavsicinone	(1)		To	7	(120	mg,	0.500	mmol,	1.0	eq.)	was	added	NaOMe	(25%	wt	in	MeOH,	1.14	mL,	5.00	mmol,	10.0	eq.)	and	the	reaction	then	heated	at	reflux	for	four	 hours.	 The	 reaction	 was	 cooled,	 diluted	 with	 CH2Cl2	 (10	 mL),	quenched	with	NaHCO3	(10	mL),	 the	 layers	separated,	and	the	aqueous	layer	 extracted	with	 CH2Cl2	 (3	 ×	 10	mL).	 The	 combined	 organic	 layers	were	 dried	 over	 MgSO4,	 and	 excess	 solvent	 removed	 in	 vacuo.	Purification	 by	 FCC	 (2%	 MeOH/CH2Cl2	 to	 5%	 MeOH/CH2Cl2)	 gave	deoxyvavsicinone	1	(17.7	mg,	0.0951	mmol,	19%)	as	an	off-white	solid;	mp	105–106	°C,	lit.	105–107	°C;24.		IR	(neat,	νmax):	2960,	2925,	1671,	1619,	1611,	1465,	1384,	771,	694	cm-1.	1H	NMR	(600	MHz,	CDCl3):	δ	8.27	(dd,	J	=	8.0,	1.3	Hz,	1H),	7.72	(ddd,	J	=	8.2,	7.2,	1.5	Hz,	1H),	7.64	(d,	J	=	8.3	Hz,	1H),	7.44	(ddd,	J	=	8.0,	7.2,	1.1	Hz,	1H),	4.20	(app	t,	J	=	7.3	Hz,	2H),	3.17	(t,	J	=	8.0	Hz,	2H),	2.28	(app	quintet,	
J	=	7.3	Hz,	2H).		13C	 NMR	 (150	MHz,	 CDCl3):	 δ	 161.2,	 159.6,	 149.3,	 134.3,	 127.0,	 126.6,	126.4,	120.7,	46.7,	32.7,	19.7.		
Rf	0.31	(2%	MeOH/EtOAc).		HRMS	 (ESI+):	 m/z	 [M+H]+	 calcd	 for	 C11H11N2O:	 	 187.0871;	 found:	187.0875.			
6,7,8,9-Tetrahydro-11H-pyrido[2,1-b]quinazolin-11-one	(3)	
33	(133	mg,	0.523	mmol)	was	cyclised	according	to	general	procedure	B.	Purification	 by	 FCC	 (1%	MeOH/CH2Cl2)	 gave	3	 (96.2	mg,	 0.481	mmol,	92%)	as	a	white	amorphous	solid;	mp	81–83	°C.		IR	(neat,	νmax)	3373,	2949,	1654,	1613,	1588,	1566,	1476,	1398	cm-1.		1H	NMR	(600	MHz,	CDCl3):	δ	8.19	(dd,	J	=	8.0,	1.2	Hz,	1H),	7.65	(ddd,	J	=	8.4,	7.2,	1.2	Hz,	1H),	7.53	(d,	J	=	8.0	Hz,	1H),	7.36	(ddd,	J	=	8.0,	7.2,	1.2	Hz,	1H),	4.02	 (t,	 J	=	6.2	Hz,	2H),	2.94	 (t,	 J	=	6.6	Hz,	2H),	1.99–1.93	 (m,	2H),	1.92–1.87	(m,	2H).		13C	 NMR	 (150	MHz,	 CDCl3):	 δ	 162.2,	 154.9,	 147.4,	 134.2,	 126.6,	 126.4,	126.1,	120.5,	42.3,	32.0,	22.2,	19.4.	
Rf	0.47	(5%	MeOH/CH2Cl2).		HRMS	 (ESI+):	 m/z	 [M+H]+	 calcd	 for	 C12H13N2O:	 201.1022;	 found:	201.1014.		Data	is	in	agreement	with	a	reported	example.13		
2,3-Dihydropyrrolo[1,2-a]quinazolin-5(1H)-one	(4)	
7	 (987	mg,	4.10	mmol)	was	cyclised	according	 to	general	procedure	B,	and	 after	 FCC	 (3%	MeOH/CH2Cl2)	 the	 title	 compound	4	 (524	mg,	 2.81	
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mmol,	69%)	was	obtained	as	a	white	amorphous	solid;	mp	213–216	°C,	lit.	217–218	°C.	IR	 (neat,	 νmax):	3059,	2953,	2925,	2897,	1634,	1593,	1533,	1501,	1461,	1420,	778	cm-1.	1H	NMR	(600	MHz,	CDCl3):	δ	8.25	(dd,	J	=	8.0,	1.1	Hz,	1H),	7.66	(ddd,	J	=	8.4,	7.3,	1.5	Hz,	1H),	7.40	(ddd,	J	=	8.1,	7.3,	0.9	Hz,	1H),	7.17	(d,	J	=	8.2	Hz,	1H),	4.22		(app	t,	J	=	7.4	Hz,	2H),	3.15	(app	t,	J	=	7.8	Hz,	2H),	2.41–2.36	(m,	2H).		13C	 NMR	 (150	MHz,	 CDCl3):	 δ	 170.3,	 166.5,	 138.8,	 133.7,	 128.9,	 125.9,	118.9,	114.6,	48.8,	32.9,	18.7.		Rf	0.17	(5%	MeOH/C12Cl2).		HRMS	 (ESI+):	 m/z	 [M+H]+	 calcd	 for	 C11H11N2O:	 	 187.0866;	 found:	187.0870.				
2-(4-Chlorobutanamido)benzamide	(7)	Anthranilamide	(4.95	g,	36.4	mmol)	and	4-chlorobutanoyl	chloride	(6.17	g,	 43.7	 mmol)	 were	 reacted	 according	 to	 general	 procedure	 A.	Purification	by	FCC	(gradient	50%	EtOAc/hexanes	to	5%	MeOH/EtOAc)	gave	7	 (8.08	 g,	 33.6	mmol,	 92%)	 as	 an	 off-white	 amorphous	 solid;	mp	117–119	°C,	lit.	114–115	°C;12		IR	 (neat,	 νmax):	3400,	3270,	3254,	3221,	1669,	1667,	1615,	1591,	1578,	1519,	757	cm-1.		1H	NMR	(600	MHz,	CDCl3):	δ	11.24	(s,	NH,	1H),	8.61	(d,	 J	=	8.3	Hz,	1H),	7.54	(d,	 J	=	7.8	Hz,	1H),	7.49	(dt,	 J	=	8.1,	0.8	Hz,	1H),	7.08	(t,	 J	=	7.5	Hz,	1H),	6.32	(br,	NH,	1H),	5.88	(br,	NH,	1H),	3.65	(t,	J	=	6.4	Hz,	2H),	2.60	(t,	J	=	7.1	Hz,	2H),	2.20	(quint.,	J	=	6.8	Hz,	2H).		13C	 NMR	 (150	MHz,	 CDCl3):	 δ	 171.4.	 170.8,	 140.2,	 133.5,	 127.4,	 122.9,	121.7,	118.7,	44.4,	35.2,	28.1.		
Rf	0.36	(50%	EtOAc/hexanes).		HRMS	 (ESI+):	m/z	 [M+H]+	 calcd	 for	 C11H14N2O235Cl:	 	 241.0744;	 found:	241.0744.		The	data	was	in	agreement	with	a	reported	example.12		
2-(4-Chlorobutanamido)-3-methylbenzamide	(8)	2-Amino-3-methylbenzamide	(90.0	mg,	0.599	mmol)	was	reacted	with	4-chlorobutanoyl	 chloride	 according	 to	 general	 procedure	 A.	 Purification	by	FCC	(100%	EtOAc)	gave	the	title	compound	8	(59.8	mg,	0.235	mmol,	39%)	as	a	white	amorphous	solid;	mp	145–146	°C.		IR	(neat,	νmax):	3377,	3291,	3190,	1652,	1588,	1513,	1395	cm-1.	1H	NMR	(600	MHz,	CDCl3):	δ	8.97	(s,	NH,	1H),	7.34–7.32	(m,	2H),	7.16	(t,	J	7.6	Hz,	 2H),	 6.21	 (br,	NH,	1H),	 5.63	 (br,	NH,	1H),	 3.64	 (t,	 J	 6.3	Hz,	 2H),	2.58	(t,	J	7.0	Hz,	2H),	2.24	(s,	3H),	2.21–2.16	(m,	2H).		13C	 NMR	 (150	MHz,	 CDCl3):	 δ	 171.2,	 171.0,	 136.7,	 134.6,	 134.1,	 129.7,	126.3,	125.0,	44.5,	33.8,	28.3,	19.1.		
Rf	0.50	(50%	EtOAc/hexanes)	HRMS	 (ESI+):	 m/z	 [M+Na]+	 calcd	 for	 C12H15N2O235Cl23Na:	 277.0714;	found:	277.0709.			
9-Methyl-2,3-dihydropyrrolo[1,2-a]quinazolin-5(1H)-one	(19)	
8	(42.8	mg,	0.168	mmol)	was	cyclised	according	to	general	procedure	B.	Purification	by	FCC	(4%	MeOH/CH2Cl2)	gave	19	(17.9	mg,	0.0894	mmol,	53%)	as	a	white	amorphous	solid;	mp	247–250	°C.		IR	(neat,	νmax):	1632,	1586,	1549,	1481,	1411,	785	cm-1.		1H	NMR	(600	MHz,	CDCl3):	δ	8.19	(dd,	J	=	7.9,	1.0	Hz,	1H),	7.39	(d,	J	7.3	=	Hz,	1H),	7.24	(t,	J	=	7.6	Hz,	1H),	4.66	(app	t,	J	=	7.2	Hz,	2H),	3.07	(t,	J	=	8.0	Hz,	2H),	2.73	(s,	3H),	2.32–2.27	(m,	2H).		13C	 NMR	 (125	MHz,	 CDCl3):	 δ	 170.3,	 167.8,	 138.7,	 137.7,	 127.6,	 125.9,	124.8,	120.3,	54.1,	32.7,	22.6,	19.7.		
Rf	0.14	(4%	MeOH/CH2Cl2).		
HRMS	 (ESI+):	 m/z	 [M+H]+	 calcd	 for	 C12H13N2O:	 201.2028;	 found:	201.1020.			
7-Chloro-1,2,3,4-tetrahydro-6H-pyrido[1,2-a]quinazolin-6-one	(39)	
35	(324	mg,	1.12	mmol)	was	cyclised	according	to	general	procedure	B.	Purification	 by	 FCC	 (5%	 MeOH/CH2Cl2)	 gave	 the	 desired	 product	 39	(133	 mg,	 0.567	 mmol,	 51%)	 and	 isomer	 42	 as	 white	 amorphous	powders;	mp	223–225	°C.		IR	(neat,	νmax):	3064,	2949,	2883,	1660,	1587,	1552,	1458	cm-1.		1H	NMR	(600	MHz,	CDCl3):	δ	7.50	(t,	J	=	7.8	Hz,	1H),	7.37	(dd,	J	=	7.8,	0.7	Hz,	1H),	7.31	(d,	J	=	8.4	Hz,	1H),	3.98	(app	t,	J	=	6.3	Hz,	2H),	2.98	(app	t,	J	=	6.6	Hz,	2H),	2.17–2.13	(m,	2H),	1.96–1.92	(m,	2H).		13C	 NMR	 (150	 MHz,	 CDCl3):	 δ	166.2,	 160.5,	 143.5,	 135.8,	 132.6,	 128.8,	117.6,	112.8,	47.4,	32.8,	22.8,	19.1.		
Rf	0.33	(6%	MeOH/	CH2Cl2).	HRMS	 (ESI+):	 m/z	 [M+H]+	 calcd	 for	 C12H12N2O35Cl:	 235.0633;	 found:	235.0623.			
7,8,9,10-Tetrahydroazepino[2,1-b]quinazolin-12(6H)-one	(41)	
34	(96.5	mg,	0.360	mmol)	was	cyclised	according	to	general	procedure	B.	Purification	by	FCC	(4%	MeOH/CH2Cl2)	gave	the	product	41	(40.2	mg,	0.188	mmol,	52	%)	as	a	white	amorphous	powder.		IR	(neat,	νmax):	2921,	2855,	1660,	1587,	1568,	1473,	1393	cm-1.		1H	NMR	(600	MHz,	CDCl3):	δ	8.25	(dd,	J	=	8.0,	1.4	Hz,	1H),	7.70	(ddd,	J	=	8.4,	7.2,	1.5	Hz,	1H),	7.60	(dd,	J	=	8.3,	0.6	Hz,	1H),	7.43	(ddd,	J	=	7.9,	7.2,	1.1	Hz,	1H),	4.40–4.38	(m,	2H),	3.08–3.06	(m,	2H),	1.88–1.81	(m,	6H).	13C	 NMR	 (150	MHz,	 CDCl3):	 δ	 162.1,	 159.9,	 147.6,	 134.3,	 127.2,	 126.9,	126.5,	120.4,	43.0,	37.9,	29.7,	28.3,	25.6.	
Rf	0.38	(4%	MeOH/CH2Cl2).	HRMS	 (ESI+):	 m/z	 [M+H]+	 calcd	 for	 C13H15N2O:	 215.1184;	 found:	215.1180.			
1-Chloro-6,7,8,9-tetrahydro-11H-pyrido[2,1-b]quinazolin-11-one	(42)	Side-product	 42	 was	 obtained	 from	 the	 cyclisation	 of	 35	 as	 a	 white	amorphous	solid	(113	mg,	0.538	mmol,	48%);	mp	124–127	°C.		IR	(neat,	νmax):	2949,	2883,	1660,	1587,	1552,	1458	cm-1.		1H	NMR	(600	MHz,	CDCl3):	δ	7.54	(t,	 J	=	7.8	Hz,	1H),	7.49	(d,	 J	=	7.8	Hz,	1H),	7.40	(dd,	J	=	7.8,	1.2	Hz,	1H),	4.02	(app	t,	J	=	6.0	Hz,	2H),	2.97	(app	t,	J	=	6.6	Hz,	2H),	2.03–1.97	(m,	2H),	1.95–1.91	(m,	2H).		13C	 NMR	 (150	MHz,	 CDCl3):	 δ	 160.3,	 155.9,	 149.6,	 134.0,	 133.7,	 129.0,	125.7,	117.6,	42.8,	31.9,	22.3,	19.3.		
Rf	0.47	(EtOAc).		HRMS	 (ESI+):	 m/z	 [M+H]+	 calcd	 for	 C12H13N2O35Cl:	 235.0638;	 found:	235.0641.			
5-Chloro-2-(4-chlorobutyl)quinazolin-4(3H)-one	(42a)		Side-product	 42a	 (7.0	 mg,	 0.0258	 mmol,	 9%)	 was	 obtained	 from	quenching	 the	 cyclisation	 of	 35	 with	 tBuOK	 after	 one	 hour	 and	purification	by	FCC	 (50%	MeOH/hexanes)	as	a	white	amorphous	 solid;	decomposition	215	°C.		IR	(neat,	νmax):	3174,	3037,	2962,	2901,	1679,	1619,	1594,	1457,	817	cm-1.		1H	NMR	(600	MHz,	CDCl3):	δ	11.71	(s,	NH),	7.63–7.59	(m,	2H),	7.46	(dd,	J	=	6.8,	2.1	Hz,	1H),	3.61	(t,	 J	=	6.6	Hz,	2H),	2.81	(t,	 J	=	7.7	Hz,	2H),	2.09–2.03	(m,	2H),	1.97–1.92	(m,	2H).		13C	 NMR	 (150	MHz,	 CDCl3):	 δ	 161.7,	 155.9,	 151.0,	 133.4,	 133.2,	 128.4,	125.8,	117.0,	43.5,	33.8,	31.1,	23.6.		
Rf	0.36	(50%	EtOAc/hexanes).	
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HRMS	 (ESI+):	m/z	 [M+H]+	 calcd	 for	 C12H13N2O35Cl2:	 271.0399;	 found:	271.0387.			
1-Chloro-7,8,9,10-tetrahydroazepino[2,1-b]quinazolin-12(6H)-one	(43)	
36	 (13.0	mg,	 0.0456	mmol,	 1.0	 eq.)	 was	 cyclised	 according	 to	 general	procedure	 B.	 Purification	 by	 preparative	 TLC	 (4%	MeOH/CH2Cl2)	 gave	the	 product	 43	 (2.3	 mg,	 0.00925	 mmol,	 20%)	 as	 a	 white	 amorphous	powder.		IR	(neat,	νmax):	2919,	2851,	1664,	1595,	1548,	1457	cm-1.	1H	NMR	(600	MHz,	CDCl3):	δ	7.55	(t,	J	=	7.9	Hz,	1H),	7.50	(dd,	J	=	8.2,	1.3	Hz,	1H),	7.42	(dd,	 J	=	7.7,	1.3	Hz,	1H),	4.36–4.35	(m,	2H),	3.04–3.02	(m,	2H),	1.90–1.79	(m,	6H).		13C	 NMR	 (150	MHz,	 CDCl3):	 δ	 160.6,	 160.2,	 150.0,	 134.4,	 133.7,	 129.3,	126.3,	117.6,	43.1,	37.8,	29.7,	28.1,	25.5.		
Rf	0.27	(4%	MeOH/CH2Cl2).	HRMS	 (ESI+):	 m/z	 [M+H]+	 calcd	 for	 C13H14N2O35Cl:	 249.0795;	 found:	249.0797.	
	
5-Chloro-2-(5-chloropentyl)quinazolin-4(3H)-one	(43a)	
43a	 (13.0	 mg,	 0.0456	 mmol,	 95%)	 was	 obtained	 from	 quenching	 the	cyclisation	of	36	(14.5	mg,	0.0478	mmol)	with	tBuOK	after	24	hours	and	purification	by	FCC	(2%	MeOH/CH2Cl2)	as	a	white	amorphous	solid;	mp	160–161	°C.		IR	(neat,	νmax):	2956,	2932,	2902,	2869,	1674,	1617,	1600,	1462,	cm-1.	1H	NMR	(600	MHz,	CDCl3):	δ	11.91	(s,	NH),	7.64–7.60	(m,	2H),	7.46	(dd,	J	=	 6.8,	 2.1	Hz,	 1H),	 3.56	 (t,	 J	 =	 6.5	Hz,	 2H),	 2.80	 (app	 t,	 J	=	7.9	Hz,	 2H),	1.97–1.92	(m,	2H),	1.90–1.85	(m,	2H),	1.65–1.60	(m,	2H).	13C	 NMR	 (150	MHz,	 CDCl3):	 δ	 162.8,	 157.4,	 152.1,	 134.3,	 134.1,	 129.3,	126.7,	118.0,	44.9,	35.6,	32.3,	26.69,	26.67.	
Rf	0.37	(2%	MeOH/CH2Cl2).		HRMS	(ESI+):	m/z	[M+Na]+	calcd	for	C13H14N2O35Cl2Na:	307.0375;	found:	307.0369.		
(E)-3-Benzylidene-2,3-dihydropyrrolo[1,2-a]quinazolin-5(1H)-one	(44)	Adapted	 from	a	 literature	protocol,25	 to	a	solution	of	4	 (59.2	mg,	0.318	mmol,	 1.0	eq.)	 in	 AcOH	 (1.00	 mL)	 was	 added	 benzaldehyde	 (65.7	 μL,	0.350	mmol,	1.1	eq.)	then	sodium	acetate	(21.0	mg,	0.260	mmol,	0.8	eq.).	The	 reaction	 was	 heated	 at	 reflux	 for	 four	 hours,	 cooled	 to	 room	temperature,	then	the	solids	were	filtered,	and	washed	with	H2O,	CH2Cl2,	and	EtOH	successively,	giving	52	(82.9	mg,	0.302	mmol,	95%)	as	a	white	amorphous	solid;	mp	290–293	°C.		IR	(neat,	νmax):	1634,	1598,	1538,	1493,	1465,	1426,	1139,	757,	688	cm-1.		1H	NMR	(600	MHz,	CDCl3):	δ	8.27	(d,	J	=	7.8	Hz,	1H),	7.93	(s,	1H),	7.65	(t,	J	=	7.6	Hz,	1H),	7.49	(d,	J	=	7.4	Hz,	2H),	7.41–7.32	(m,	3H),	7.20	(d,	J	=	8.3	Hz,	1H),	4.30	(t,	J	=	7.0	Hz,	2H),	3.38–3.37	(m,	2H).		13C	 NMR	 (150	MHz,	 CDCl3):	 δ	 170.5,	 161.4,	 138.9,	 135.3,	 133.8,	 133.5,	130.2,	129.5,	129.03,	128.97,	126.3,	119.9,	114.5,	46.3,	25.4.		
Rf	0.25	(4%	MeOH/CH2Cl2).		HRMS	 (ESI+):	 m/z	 [M+H]+	 calcd	 for	 C18H15N2O:	 275.1184;	 found:	275.1176.				
(E)-3-(2-Ethylbutylidene)-2,3-dihydropyrrolo[1,2-a]quinazolin-5(1H)-one	(47)		To	a	solution	of	4	(50.0	mg,	0.269	mmol)	in	CH2Cl2	(920	μL)	tBuOK	(36.1	mg,	0.322	mmol,	1.2	eq.)	was	added,	the	mixture	stirred	vigorously	for	5	minutes,	 then	2-ethylbutyraldehyde	 (33.1	µL,	0.269	mmol,	1.0	eq.)	was	added.	After	1	hour	NaHCO3	(10	mL)	and	CH2Cl2	(10	mL)	were	added,	the	layers	 separated,	 and	 the	 aqueous	 layer	 extracted	with	 CH2Cl2	 (3	×	 10	mL).	 The	 combined	 organic	 layers	 were	 dried	 over	 MgSO4	 and	 excess	
solvent	 removed	 in	 vacuo.	 Purification	 by	 preparative	 TLC	 (5%	MeOH/CH2Cl2)	 gave	 the	product	47	 (49.8	mg,	0.186	mmol,	69%)	as	an	off-white	amorphous	solid;	decomposition	113–115	°C.		IR	 (neat,	 νmax):	2958,	2929,	2874,	2857,	1637,	1626,	1598,	1532,	1496,	1461,	1423,	741	cm-1.		1H	NMR	(600	MHz,	CDCl3):	δ	8.31	(dd,	J	=	7.9,	1.3	Hz,	1H),	7.66	(dt,	J	=	7.4,	1.6	Hz,	1H),	7.41	(dt,	J	=	7.4,	0.8	Hz,	1H),	7.19	(d,	J	=	8.2	Hz,	1H),	6.92	(dt,	J	=	10.8,	2.7	Hz,	1H),	4.20	 (t,	 J	 =	7.4	Hz,	2H),	3.02	 (m,	2H),	2.19-2.14	 (m,	1H),	1.61-1.50	(m,	2H,	1.42-1.34	(m,	2H),	t,	J	=	7.8	Hz,	6H).			13C	 NMR	 (150	MHz,	 CDCl3):	 δ	 170.6,	 160.3,	 142.4,	 139.0,	 133.7,	 131.4,	129.0,	126.1,	119.9,	114.3,	45.8,	44.3,	27.7,	23.2,	12.1.		
Rf	0.30	(4%	MeOH/CH2Cl2).		HRMS	(ESI+):	m/z	calcd	for	C17H21N2O:	269.164;	found:	269.1658.		
	(E)-6-chloro-3-((tetrahydro-2H-pyran-4-yl)methylene)-2,3-
dihydropyrrolo[1,2-a]quinazolin-5(1H)-one	(50)		To	 a	 solution	 of	28	 (50.0	mg,	 0.227	mmol,	 1.0	 eq)	 in	 CH2Cl2	 (920	 μL)	
tBuOK	 (30.5	 mg,	 0.272	 mmol,	 1.2	 eq.)	 was	 added,	 the	 mixture	 stirred	vigorously	 for	 5	 minutes,	 then	 tetrahydro-2H-pyrane-4-carbaldehyde	(0.250	 mmol,	 1.1	 eq.)	 was	 added.	 After	 1	 hour	 NaHCO3	 (10	 mL)	 and	CH2Cl2	(10	mL)	were	added,	the	layers	separated,	and	the	aqueous	layer	extracted	with	 CH2Cl2	 (3	×	 10	mL).	 The	 combined	 organic	 layers	were	dried	over	MgSO4	and	excess	solvent	 removed	 in	vacuo.	Purification	by	preparative	 TLC	 (5%	 MeOH/CH2Cl2)	 gave	 the	 product	 50	 (48.4	 mg,	0.153	mmol,	67%)	as	an	off-white	amorphous	solid;	decomposition	211–214	°C.		IR	(neat,	νmax):	2931,	2832,	1645,	1602,	1585,	1543,	1488	cm-1.		1H	NMR	(600	MHz,	CDCl3):	δ	7.52	(t,	J	=	8.1	Hz,	1H),	7.41	(dd,	J	=	7.8,	0.7	Hz,	1H),	7.08	(dd,	J	=	8.3,	0.7	Hz	1H),	6.98	(dt,	J	=	9.7,	2.8	Hz,	1H),	4.19	(t,	J	=	7.3	Hz,	2H),	4.01	(dt,	J	=	11.5,	3.4	Hz,	2H),	3.50–3.45	(m,	2H),	3.06	(dt,	J	=	7.3,	2.8	Hz,	2H),	2.59–2.53	(m,	1H),	1.66–1.62	(m,	4H).		13C	 NMR	 (150	MHz,	 CDCl3):	 δ	 168.1,	 159.5,	 141.2,	 140.5,	 136.6,	 133.0,	130.0,	129.1,	116.9,	113.2,	67.3,	46.5,	36.6,	31.3,	22.6.		
Rf	0.33	(5%	MeOH/CH2Cl2).		HRMS	(ESI+):	m/z	calcd	for	C17H18N2O235Cl:	317.1052;	found:	317.1056.		
(E)-3-((Dimethylamino)methylene)-2,3-dihydropyrrolo[1,2-a]quinazolin-
5(1H)-one	(51)	To	 a	 solution	 of	4	 (372	mg,	 2.00	mmol,	 1.0	 eq)	 in	 DMF	 (6.7	mL)	 was	added	was	added	POCl3	(373	μL,	4.00	mmol,	2.0	eq.).	Purification	by	FCC	(4%	 MeOH/CH2Cl2)	 gave	 51	 (357	 mg,	 1.48	 mmol,	 74%)	 as	 a	 tan	amorphous	solid;	decomposition	251–252	°C.		IR	 (neat,	 νmax):	1646,	1622,	1598,	1514,	1495,	1397,	1373,	1314,	1109,	776	cm-1.		1H	NMR	(600	MHz,	d6-DMSO):	δ	7.92	(dd,	J	=	7.8,	1.2	Hz,	1H),	7.64	(ddd,	J	=	7.8,	7.2,	1.2	Hz,	1H),	7.39	(t,	J	=	1.2	Hz,	1H),	7.27	(dt,	J	=	7.5,	0.6	Hz,	1H),	7.23	(d,	J	=	8.4	Hz,	1H),	4.10–4.08	(m,	2H),	3.21	(t,	J	=	7.8	Hz,	2H),	3.09	(s,	6H).		13C	 NMR	 (150	MHz,	 CDCl3):	 δ	 168.2,	 163.9,	 144.0,	 139.5,	 132.9,	 127.1,	123.4	,	118.8,	114.2,	94.5,	45.4,	40.0,	22.7.	
Rf	0.21	(5%	MeOH/CH2Cl2).		HRMS	 (ESI+):	 m/z	 [M+H]+	 calcd	 for	 C14H16N3O:	 	 242.1293;	 found:	242.1295.			
(E)-3-(Piperidin-1-ylmethylene)-2,3-dihydropyrrolo[1,2-a]quinazolin-
5(1H)-one	(52)	To	a	solution	of	4	(59.0	mg,	0.317	mmol,	1.0	eq.)	in	CH2Cl2	(1.00	mL)	was	added	1-formylpiperazine	(107	μL,	0.951	mmol,	3.0	eq.)	and	POCl3	(59.1	μL,	0.634	mmol,	2.0	eq.).	The	reaction	mixture	was	refluxed	for	28	hours,	cooled	to	room	temperature,	diluted	with	CH2Cl2	(10	mL)	and	quenched	with	NaHCO3	(10	mL).	The	aqueous	layer	was	extracted	with	CH2Cl2	(5	×	
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10	mL),	the	combined	layers	dried	over	MgSO4,	and	solvent	removed	 in	
vacuo.	Purification	by	FCC	(2%	MeOH/CH2Cl2	to	5%	MeOH/CH2Cl2)	gave	the	title	compound	52	(28.9	mg,	0.103	mmol,	32%)	as	a	tan	amorphous	solid.		IR	 (neat,	 νmax):	 2934,	 2853,	 1643,	 1600,	 1587,	 1510,	 1486,	 1439,	 1402	cm-1.		1H	NMR	(600	MHz,	d6-DMSO):	δ	7.93	(dd,	J	=	7.8,	1.2	Hz,	1H),	7.64	(ddd,	J	=	8.4,	7.8,	1.2	Hz,	1H),	7.40	(s,	1H),	7.27	(dt,	J	=	7.8,	0.6	Hz,	1H),	7.24	(d,	J	=	8.4	Hz,	1H),	4.11	(app	t,	J	=	7.8	Hz,	2H),	3.47–3.45	(m,	4H),	3.11	(app	t,	J	=	7.8	Hz,	2H),	1.63–1.57	(m,	6H).		13C	 NMR	 (100	MHz,	 CDCl3):	 δ	 168.1,	 164.1,	 142.4,	 139.5,	 132.9,	 127.2,	123.4,	118.8,	114.2,	93.9,	50.9,	45.5,	26.1,	23.6,	23.2.		
Rf	0.30	(5%	MeOH/CH2Cl2).		HRMS	 (ESI+):	 m/z	 [M+H]+	 calcd	 for	 C17H20N3O:	 	 282.1606;	 found:	282.1615.		
(E)-3-(Morpholinomethylene)-2,3-dihydropyrrolo[1,2-a]quinazolin-5(1H)-
one	(53)	To	a	solution	of	4	(50.0	mg,	0.269	mmol,	1.0	eq.)	in	CH2Cl2	(1.35	mL)	was		added	 morpohline-4-carbaldehyde	 (310	 mg,	 2.69	 mmol,	 10.0	 eq.)	 and	POCl3	(50.1	μL,	0.538	mmol,	2.0	eq.).	The	reaction	mixture	was	refluxed	for	 three	 hours,	 diluted	 with	 CH2Cl2	 (10	 mL)	 cooled	 to	 room	temperature,	 and	 quenched	 with	 NaHCO3	 (15	 mL).	 The	 aqueous	 layer	was	extracted	with	CH2Cl2	 (5	×	15	mL),	 the	combined	 layers	dried	over	Na2SO4,	 and	 solvent	 removed	 in	 vacuo.	 Purification	 by	 FCC	 (5%	MeOH/CH2Cl2	 to	10%	MeOH/CH2Cl2)	 gave	 the	 title	 compound	53	 (26.7	mg,	0.0942	mmol,	35%)	as	a	tan	amorphous	solid;	decomposition	275	°C.		IR	 (neat,	 νmax)	 2961,	 2925,	 2887,	 1634,	 1600,	 1594,	 1525,	 1510,	 1110,	760	cm-1.		1H	NMR	(600	MHz,	CDCl3):	δ	8.29	(dd,	 J	=	7.9,	1.3	Hz,	1H),	7.65	(s,	1H),	7.59	(ddd,	J	=	8.3,	7.4,	1.6	Hz,	1H),	7.32	(ddd,	J	=	8.0,	7.5,	0.9	Hz,	1H),	7.03	(d,	 J	=	8.2	Hz,	1H),	4.14–4.11	(m,	2H),	3.76–3.75	(m,	4H),	3.51–3.48	(m,	4H),	3.50	(d,	J	=	4.8	Hz,	2H),	3.18	(ddd,	J	=	8.3,	6.7,	1.7	Hz,	2H).		13C	 NMR	 (100	MHz,	 CDCl3):	 δ	 170.3,	 164.4,	 143.0,	 139.5,	 133.2,	 128.9,	124.5,	119.4,	113.3,	95.6,	66.7,	50.4,	45.0,	24.0.		
Rf	0.25	(5%	MeOH/CH2Cl2).		HRMS	 (ESI+):	 m/z	 [M+H]+	 calcd	 for	 C16H18N3O2:	 284.1399;	 found:	284.1396.				
(E)-3-((4-Ethylpiperazin-1-yl)methylene)-2,3-dihydropyrrolo[1,2-
a]quinazolin-5(1H)-one	(54)	To	a	 solution	of	51	 (50.0	mg,	0.207	mmol,	1.0	eq)	 in	EtOH	(1	mL)	was	added	 1-ethylpiperazine	 (80.0	 µL,	 0.630	 mmol,	 0.33	 eq)	 and	 N,N-dimethylaminopyridine	 (2.5	 mg,	 0.020	 mmol,	 0.1	 eq),	 and	 heated	 at	reflux	 for	32	hours.	The	solvent	was	removed	 in	vacuo	and	purification	by	 FCC	 (5%	MeOH/DCM)	 gave	 the	 product	54	 (39.6	mg,	 0.128	mmol,	62%)	as	a	pale	brown	amorphous	solid;	mp	165–168	°C.		IR	 (neat,	 νmax):	 2970,	 2901,	 2819,	 1645,	 1613,	 1598,	 1588,	 1509,	 1491	cm-1.		1H	NMR	(600	MHz,	CDCl3):	δ	8.27	(dd,	 J	=	7.9,	1.3	Hz,	1H),	7.65	(s,	1H),	7.57	(dd,	J	=	8.4,	7.4,	1.5	Hz,	1H),	7.29	(dt,	J	=	7.8,	0.6	Hz,	1H),	7.00	(d,	J	=	7.8	Hz,	1H),	4.10	(app	t,	J	=	7.8	Hz,	2H),	3.52	(app	t,	J	=	5.0	Hz,	4H),	3.16	(dt,	J	=	7.8,	1.2	Hz,	2H),	2.51	(app	t,	J	=	4.8	Hz,	4H),	2.46	(q,	J	=	7.2	Hz,	2H),	1.10	(t,	J	=	7.2	Hz,	3H).		13C	 NMR	 (150	MHz,	 CDCl3):	 δ	 170.3,	 164.6,	 142.9,	 139.6,	 133.1,	 128.9,	124.3,	119.5,	113.2,	94.7,	52.8,	52.4,	50.3,	45.9,	24.0,	12.0.		
Rf	0.30	(5%	MeOH/CH2Cl2).		HRMS	 (ESI+):	 m/z	 [M+H]+	 calcd	 for	 C18H23N4O:	 	 311.1861;	 found:	311.1866.				
(E)-3-((4-Methyl-1,4-diazepan-1-yl)methylene)-2,3-dihydropyrrolo[1,2-
a]quinazolin-5(1H)-one	(55)	To	a	solution	of	51	(21.0	mg,	0.0870	mmol)	in	EtOH	(0.5	mL)	was	added	1-methylhomopiperazine	 (32	 µL,	 0.257	 mmol,	 3.4	 eq),	 and	 N,N-dimethylaminopyridine	 (1.1	 mg,	 0.0087	 mmol,	 0.1	 eq),	 and	 heated	 at	reflux	 for	96	hours.	The	solvent	was	removed	 in	vacuo	and	purification	by	FCC	(5%	MeOH/CH2Cl2)	gave	the	product	55	(13.2	mg,	0.0425	mmol,	49%)	as	a	pale	brown	amorphous	solid;	mp	92–94	°C.		IR	 (neat,	 νmax):	 2939,	 2913,	 2857,	 2810,	 1641,	 1602,	 1587,	 1506,	 1496	cm-1.			1H	NMR	(500	MHz,	CDCl3):	δ	8.27	(dd,	J	=	7.9,	1.4	Hz,	1H),	7.74	(t,	J	=	1.5	Hz,	1H),	7.57	(ddd,	J	=	8.3,	7.3,	1.5	Hz,	1H),	7.29	(ddd,	J	=	8.1,	7.5,	1.0	Hz,	1H),	7.00	(d,	 J	=	8.0	Hz,	1H),	4.11–4.07	(m,	2H),	3.62	(t,	 J	=	6.3	Hz,	2H),	3.59–3.57	 (m,	2H),	3.21	 (m,	2H),	2.67–2.65	 (m,	2H),	2.61–2.59	 (m,	2H),	2.39	(s,	3H),	1.95–1.91	(m,	2H).		13C	 NMR	 (125	MHz,	 CDCl3):	 δ	 170.4,	 164.6,	 144.5,	 139.7,	 133.0,	 128.8,	124.1,	119.5,	113.1,	94.1,	59.1,	57.0,	54.1,	51.7,	46.9,	45.8,	28.5,	23.9.		
Rf	0.32	(10%	MeOH/CH2Cl2	+	1%	NH4OH).		HRMS	 (ESI+):	 m/z	 [M+H]+	 calcd	 for	 C18H23N4O:	 	 311.1872;	 found:	311.1884.		
	
Tert-Butyl	 (E)-4-((5-oxo-1,2-dihydropyrrolo[1,2-a]quinazolin-3(5H)-
ylidene)methyl)piperazine-1-carboxylate	(56)	To	a	solution	of	51	(21.0	mg,	0.0870	mmol)	in	EtOH	(0.5	mL)	was	added	with	 1-boc-piperazine	 (49.0	 mg,	 0.263	 mmol,	 3.0	 eq)	 and	 N,N-dimethylaminopyridine	 (1.1	 mg,	 0.0087	 mmol,	 0.1	 eq),	 and	 heated	 at	reflux	 for	96	hours.	The	solvent	was	removed	 in	vacuo	and	purification	by	FCC	(5%	MeOH/CH2Cl2)	gave	the	product	56	(20.0	mg,	0.0522	mmol,	60%)	as	a	pale	brown	amorphous	solid;	decomposition	140	°C.		IR	 (neat,	 νmax):	 2974,	 2918,	 1688,	 1644,	 1605,	 1591,	 1518,	 1494,	 1405	cm-1.		1H	NMR	(600	MHz,	CDCl3):	δ	8.24	(dd,	J	=	7.4,	1.2	Hz,	1H),	7.57	(m,	1H),	7.54	(ddd,	J	=	8.4,	7.4,	1.4	Hz,	1H),	7.27	(dt,	J	=	7.9,	0.6	Hz,	1H),	6.97	(d,	J	=	8.1	Hz,	1H),	4.07	(app	t,	J	=	7.9	Hz,	2H),	3.48–3.46	(m,	4H),	3.39	(br,	4H),	3.10	(dt,	J	=	7.8,	1.4	Hz,	2H),	1.46	(s,	9H).		13C	 NMR	 (150	MHz,	 CDCl3):	 δ	 170.2,	 164.3,	 154.5,	 142.5,	 139.5,	 133.0,	128.6,	 124.2,	 119.4,	 113.4,	 95.8,	 80.8,	 46.0,	 28.6,	 24.0.	 *	 C13	 and	 C14	were	 weak	 and	 very	 broad	 in	 13C	 NMR	 and	 could	 not	 be	 reliably	assigned.	
Rf	0.25	(5%	MeOH/CH2Cl2).		HRMS	 (ESI+):	 m/z	 [M+H]+	 calcd	 for	 C21H27N4O3:	 383.2078;	 found:	383.2070.			
(E)-7-Chloro-4-((dimethylamino)methylene)-1,2,3,4-tetrahydro-6H-
pyrido[1,2-a]quinazolin-6-one	(57)	To	a	stirred	solution	of	40	(88.0	mg,	0.37	mmol,	1.0	eq.)	in	DMF	(740	μL)	was	 added	 POCl3	 (69.9	 μL,	 0.74	 mmol,	 2.0	 eq.)	 and	 the	 reaction	 was	heated	 to	 60	 °C	 for	 6	 hours.	 The	 reaction	 was	 cooled	 to	 room	temperature,	 diluted	with	 CH2Cl2	 (15	mL),	 and	 quenched	with	NaHCO3	(15	mL).	The	aqueous	layer	was	extracted	with	CH2Cl2	(5	×	15	mL),	the	combined	 organic	 layers	 dried	 over	 Na2SO4	 and	 solvent	 removed	 in	
vacuo.	 The	 residue	 was	 co-evaporated	 with	 toluene	 (3	 ×	 5	 mL)	 and	purification	 by	 FCC	 (6%	MeOH/CH2Cl2)	 gave	 the	 product	57	 (52.0	mg,	0.18	mmol,	49%)	as	a	yellow	amorphous	solid;	mp	197–200	°C.		IR	 (neat,	 νmax):	 3111,	 2944,	 2885,	 2813,	 1607,	 1587,	 1499,	 1481,	 1464	cm-1.		1H	NMR	(600	MHz,	CDCl3):	δ	8.27	(s,	1H),	7.39	(t,	J	=	8.2	Hz,	1H),	7.29	(dd,	
J	=	7.9,	0.9	Hz,	1H),	7.14	(dd,	J	=	8.5,	0.6	Hz,	1H),	3.85	(app	t,	J	=	6.0	Hz,	2H),	3.12	(s,	6H),	2.73–2.71	(m,	2H),	2.09–2.05	(m,	2H).		13C	 NMR	 (150	MHz,	 CDCl3):	 δ	 168.9,	 158.6,	 151.1,	 144.4,	 135.2,	 131.2,	127.0,	117.7,	111.7,	94.2,	46.9,	43.8,	23.4	,	22.5.		
Rf	0.43	(6%	MeOH/CH2Cl2).		
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HRMS	 (ESI+):	 m/z	 [M+H]+	 calcd	 for	 C15H17N3O35Cl:	 290.1055;	 found:	290.1048.		
(E)-7-Chloro-4-((4-methylpiperazin-1-yl)methylene)-1,2,3,4-tetrahydro-
6H-pyrido[1,2-a]quinazolin-6-one	(58)	To	a	solution	of	57	(26.0	mg,	0.09	mmol,	1.0	eq.)	 in	EtOH	(450	μL)	 in	a	microwave	vial	was	added	1-methylpiperazine	(49.7	μL,	0.45	mmol,	5.0	eq.)	and	DMAP	(1.1	mg,	0.009	mmol,	0.1	eq.).	The	vial	was	sealed	and	the	reaction	heated	at	70	°C	for	6	hours,	 then	cooled	to	room	temperature,	diluted	with	CH2Cl2	(10	mL)	and	NaHCO3	(10	mL).	The	aqueous	layer	was	extracted	with	 CH2Cl2	 (5	 ×	 10	mL),	 the	 combined	 organic	 layers	 dried	over	Na2SO4,	 and	excess	 solvent	was	 removed	 in	 vacuo.	 Purification	by	FCC	(10%	MeOH/CH2Cl2	+	0.5%	NH4OH)	gave	the	product	58	(27.6	mg,	0.080	mmol,	89%)	as	a	yellow	amorphous	solid;	mp	174–177	°C.		IR	(neat,	νmax):	2934,	2845,	2790,	1615,	1586,	1494,	1474,	1419	cm-1.		1H	NMR	(600	MHz,	CDCl3):	δ	8.24	(s,	1H),	7.39	(t,	J	=	8.2	Hz,	1H),	7.28	(dd,	
J	=	7.8,	0.7	Hz,	1H),	7.14	(d,	 J	=	8.4	Hz,	1H),	3.85	(app	t,	 J	=	6.0	Hz,	2H),	3.53	(m,	4H),	2.60	(app	t,	J	=	6.1	Hz,	2H),	2.43	(m,	4H),	2.30	(s,	3H),	2.08	(app	quintet,	J	=	6.0	Hz,	2H).		13C	 NMR	 (150	MHz,	 CDCl3):	 δ	 165.9,	 158.3,	 149.3,	 144.2,	 135.1,	 131.7,	127.0,	117.7,	111.7,	94.8,	55.2,	51.2,	46.7,	46.2,	24.2,	22.3.		
Rf	0.22	(10%	MeOH/CH2Cl2	+	0.5%	NH4OH).		HRMS	 (ESI+):	 m/z	 [M+H]+	 calcd	 for	 C18H22N4O35Cl:	 345.1482;	 found:	345.1494.		
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